Kos Pharmaceuticals, Inc (KOSP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Doc Bones	3/30/2005 8:59:14 AM
	of 118

Barr, Kos in talks over cholesterol drug patent KOSP up about $6 Wed Mar 30, 2005 08:42 AM ET CHICAGO, March 30 (Reuters) - Drugmakers Barr Pharmaceuticals, Inc. (BRL.N: Quote, Profile, Research) and Kos Pharmaceuticals, Inc. (KOSP.O: Quote, Profile, Research) on Wednesday said they are negotiating to settle a dispute over a patent on Kos' cholesterol drug Niaspan. The two drugmakers have been battling over Barr's bid to sell a generic or copycat form of Niaspan, which had sales of more than $300 million in 2004. The companies now expect the U.S. District Court for the Southern District of New York to discontinue and stay all proceedings to let them negotiate a deal, with the option of each party reactivating the matter if no deal is reached. yahoo.reuters.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next